News

TSO3 TO EVALUATE STRATEGIC ALTERNATIVES IN PARALLEL WITH US REGULATORY APPROVAL PROCESS

Quebec City, June 18, 2013 – TSO3 Inc. (“TSO3”) an innovator in low-temperature sterilization technology for medical devices in healthcare settings, today announced that while it is pursuing the US regulatory approval for the STERIZONE® 125L+ Sterilizer and continuing commercial negotiations on a non-exclusive basis, TSO3 has initiated a process to assess the range of strategic alternatives available to the Company, as a means to maximize shareholder value once regulatory clearance has been achieved.

Read more

News

TSO3 APPOINTS CLAUDE MICHAUD AND JEAN LAMARRE TO THE BOARD OF DIRECTORS – These appointments follow the departures of André de Villers and Jacques Marcotte

Quebec City, March 20, 2013 – Mr. Germain Carrière, Chairman of the Board of TSO3 Inc. (“TSO3”) (TSX: TOS), is pleased to announce the appointment of Mr. Claude Michaud and Mr. Jean Lamarre to the Board of Directors, following the departures of long standing members Dr. André de Villers and Dr. Jacques Marcotte.

Read more

News

TSO3 ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER 2013

Quebec City, May 8, 2013 – TSO3 Inc. (“TSO3”) (TSX: TOS) an innovator in low temperature sterilization technology for medical devices in healthcare settings, posted today its financial results for the first quarter of 2013 ended March 31.

Read more

News

FISCAL 2012 ANNUAL MEETING OF SHAREHOLDERS – MAY 8 2013

Quebec City, April 29, 2013 – TSO3 Inc. (“TSO3”) (TSX: TOS) will report first quarter (Q1) 2013 financial results, for the period ending March 31, 2013 via press release on Wednesday May 8, 2013. TSO3 will also hold its fiscal 2012 Annual General Meeting of Shareholders at 3:00 P.M. (EDST) the same day.

Read more

News

US REGULATORY AGENCY PROVIDES FAVORABLE REVIEW AND RECOMMENDS PATH FOR APPROVAL – TSO3 to pursue de novo Process Classification

Quebec City, April 17, 2013 – TSO3 Inc. (“TSO3”) an innovator in low-temperature sterilization technology for medical devices in healthcare settings, today announced that upon review of the current 510(k) submission for the STERIZONE® 125L+ Sterilizer, the US Regulatory Agency has recognized the quality of the science provided and the performance of the device, as well as the uniqueness of the TSO3 proprietary technology. The Agency is of the opinion that there is no predicate to this device available on the market and that it is eligible for the de novo classification as a new standard. After evaluation of this option, the Company has decided to pursue the de novo approval pathway. The Company believes that this will not affect the overall timeline for approval to market.

Read more